Wenqing Wang, Justine Gibson, Sara Horsman, Deirdre Mikkelsen, François-René Bertin
Background
Altered gut microbiota has been associated with dopaminergic degenerative diseases in people, but studies on horses with pituitary pars intermedia dysfunction (PPID) are lacking.
Hypothesis/Objectives
Investigate the effect of PPID on fecal microbiota in horses.
Animals
Nine horses with PPID and 13 age-matched control horses.
Methods
Prospective control study. Fecal samples were collected bimonthly. Microbial analysis used 16S rRNA sequencing to determine the relative abundance at genus and phylum levels, assess alpha and beta diversity and identify core microbiota.
Results
Horses with PPID had decreased relative abundances of Christensenellaceae R-7 group (median; 95% confidence interval [CI]: PPID, 2.04; 1.82-2.35 vs control, 2.54; 2.37-2.76; P = .02) and NK4A214 group (PPID, 2.21; 2.02-2.56 vs control, 2.62; 2.44-2.85; P = .05), and significant lower abundances of Romboutsia (log2FoldChange = −3.54; P = .04) and Peptococcaceae uncultured (log2FoldChange = −0.89; P = .04) by differential abundance analysis. However, the abundance of Fibrobacter (log2FoldChange = 0.74; P = .04) was significantly higher in the PPID group. A significant effect of PPID on beta diversity was observed (P = .004), whereas alpha diversity varied with months (P = .001). Seven unique genera were identified in horses with PPID and 12 in control horses.
Conclusions and Clinical Importance
The fecal microbial composition is altered in horses with PPID. These findings support the potential role of the microbiota-gut-brain axis in the pathogenesis of PPID.
{"title":"Characterization and comparison of fecal microbiota in horses with pituitary pars intermedia dysfunction and age-matched controls","authors":"Wenqing Wang, Justine Gibson, Sara Horsman, Deirdre Mikkelsen, François-René Bertin","doi":"10.1111/jvim.17288","DOIUrl":"10.1111/jvim.17288","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Altered gut microbiota has been associated with dopaminergic degenerative diseases in people, but studies on horses with pituitary pars intermedia dysfunction (PPID) are lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis/Objectives</h3>\u0000 \u0000 <p>Investigate the effect of PPID on fecal microbiota in horses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Nine horses with PPID and 13 age-matched control horses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective control study. Fecal samples were collected bimonthly. Microbial analysis used 16S rRNA sequencing to determine the relative abundance at genus and phylum levels, assess alpha and beta diversity and identify core microbiota.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Horses with PPID had decreased relative abundances of <i>Christensenellaceae</i> R-7 group (median; 95% confidence interval [CI]: PPID, 2.04; 1.82-2.35 vs control, 2.54; 2.37-2.76; <i>P</i> = .02) and NK4A214 group (PPID, 2.21; 2.02-2.56 vs control, 2.62; 2.44-2.85; <i>P</i> = .05), and significant lower abundances of <i>Romboutsia</i> (log2FoldChange = −3.54; <i>P</i> = .04) and <i>Peptococcaceae uncultured</i> (log2FoldChange = −0.89; <i>P</i> = .04) by differential abundance analysis. However, the abundance of <i>Fibrobacter</i> (log2FoldChange = 0.74; <i>P</i> = .04) was significantly higher in the PPID group. A significant effect of PPID on beta diversity was observed (<i>P</i> = .004), whereas alpha diversity varied with months (<i>P</i> = .001). Seven unique genera were identified in horses with PPID and 12 in control horses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>The fecal microbial composition is altered in horses with PPID. These findings support the potential role of the microbiota-gut-brain axis in the pathogenesis of PPID.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giovanni Grosso, Rosalba Tognetti, Oriol Domenech, Andrea Della Pina, Federica Marchesotti, Valentina Patata, Tommaso Vezzosi
Background
Evaluating the size of the pulmonary artery (PA) is key for the echocardiographic assessment of pulmonary hypertension (PH) in dogs.
Hypothesis/Objectives
To compare the diagnostic accuracy of the main PA (MPA) and right PA (RPA) sizes for the echocardiographic detection of PH in dogs, and to evaluate differences between precapillary and postcapillary PH dogs.
Animals
Four hundred four dogs; 136 controls and 268 with PH.
Methods
Prospective, multicenter, observational study. The MPA, maximum and minimum RPA diameter were normalized to body weight (MPA_N, RPAmax_N, and RPAmin_N). The MPA was also indexed to the ascending aorta (MPA/AO), while the RPA size was indexed to the aortic annulus (RPAmax/Aod and RPAmin/Aod). The right pulmonary artery distensibility index (RPADi) was also calculated. The diagnostic accuracy of PA parameters for PH was assessed through the receiver operating characteristic curve analysis and area under the curve (AUC). Measurement variability was assessed trough the coefficient of variation (CV).
Results
The RPADi, RPAmin_N, and RPAmin/Aod showed similar diagnostic accuracy for the detection of PH (AUC = 0.975, AUC = 0.971, and AUC = 0.953, respectively), higher than MPA/AO (AUC = 0.926), MPA_N (AUC = 0.880), RPAmax_N (AUC = 0.814), and RPAmax/Aod (AUC = 0.803; P < .05). Aside from RPAmax variables, no differences were found between precapillary and postcapillary PH. RPA size parameters showed lower CVs in comparison to MPA/AO and RPADi.
Conclusions and Clinical Importance
Although MPA/AO showed an excellent sensitivity and specificity for the detection of PH, the RPAmin exhibited a higher diagnostic accuracy and less measurement variability, thus could represent a new useful parameter for the detection of PH in dogs.
{"title":"Echocardiographic evaluation of the size of the main pulmonary artery and right pulmonary artery in dogs with pulmonary hypertension","authors":"Giovanni Grosso, Rosalba Tognetti, Oriol Domenech, Andrea Della Pina, Federica Marchesotti, Valentina Patata, Tommaso Vezzosi","doi":"10.1111/jvim.17241","DOIUrl":"10.1111/jvim.17241","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evaluating the size of the pulmonary artery (PA) is key for the echocardiographic assessment of pulmonary hypertension (PH) in dogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis/Objectives</h3>\u0000 \u0000 <p>To compare the diagnostic accuracy of the main PA (MPA) and right PA (RPA) sizes for the echocardiographic detection of PH in dogs, and to evaluate differences between precapillary and postcapillary PH dogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Four hundred four dogs; 136 controls and 268 with PH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective, multicenter, observational study. The MPA, maximum and minimum RPA diameter were normalized to body weight (MPA_N, RPAmax_N, and RPAmin_N). The MPA was also indexed to the ascending aorta (MPA/AO), while the RPA size was indexed to the aortic annulus (RPAmax/Aod and RPAmin/Aod). The right pulmonary artery distensibility index (RPADi) was also calculated. The diagnostic accuracy of PA parameters for PH was assessed through the receiver operating characteristic curve analysis and area under the curve (AUC). Measurement variability was assessed trough the coefficient of variation (CV).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The RPADi, RPAmin_N, and RPAmin/Aod showed similar diagnostic accuracy for the detection of PH (AUC = 0.975, AUC = 0.971, and AUC = 0.953, respectively), higher than MPA/AO (AUC = 0.926), MPA_N (AUC = 0.880), RPAmax_N (AUC = 0.814), and RPAmax/Aod (AUC = 0.803; <i>P</i> < .05). Aside from RPAmax variables, no differences were found between precapillary and postcapillary PH. RPA size parameters showed lower CVs in comparison to MPA/AO and RPADi.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Although MPA/AO showed an excellent sensitivity and specificity for the detection of PH, the RPAmin exhibited a higher diagnostic accuracy and less measurement variability, thus could represent a new useful parameter for the detection of PH in dogs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jocelyn Mott, Arnon Gal, Antonio Maria Tardo, Alisa Berg, Riley Claude, Alexis Hoelmer, Mei Lun Mui, Avin Arjoonsingh, Chen Gilor
Background
The advantages of insulin degludec 100 U/mL (IDeg100) in the treatment of diabetes mellitus (DM) include consistent release, predictable glucose-lowering effect, and minimal day-to-day variability.
Hypothesis/Objectives
To describe the use of IDeg100 in dogs with DM, level of diabetic control and adverse effects.
Animals
Thirty-three client-owned dogs with DM.
Methods
A prospective, multi-institutional, uncontrolled study of newly diagnosed or previously insulin-treated, with or without comorbidities and with or without concurrent medications. Clinical signs and continuous glucose monitoring data were monitored and guided insulin dose adjustments. A per-protocol analysis was performed.
Results
The final dose of IDeg100 in dogs was 1.3 U/kg (median, range, 0.4-2.2) achieved in 14 days (median, range, 3-32). Seventy-nine percent (26/33) of the dogs had comorbidities with 42% (11/26) having more than 1 comorbidity. Sixty-four percent (21/33) of dogs were receiving concurrent medications with 62% (13/21) receiving more than 1 non-insulin medication. Seventy-six percent (25/33) were scored as having excellent/very good DM control. From baseline to study exit, dogs showed improvements in both ALIVE DM clinical score (from 3 [0-8, 96.49% CI (2-5)] to 1 [0-7, 96.49% CI (1-2)]; P = .0007) and average 3-day interstitial glucose (from 332.8 ± 68.7 mg/dL, 95% CI [308.8-357.2] to 229.0 ± 56.3 mg/dL [CI 209.0 - 248.9]; P < .0001).
Conclusions and Clinical Importance
Insulin degludec 100 U/mL is effective for the treatment of dogs with DM. Eighty-four percent (28/33) of dogs responded to once daily dose of IDeg100 with low frequency of clinical hypoglycemia.
{"title":"Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs","authors":"Jocelyn Mott, Arnon Gal, Antonio Maria Tardo, Alisa Berg, Riley Claude, Alexis Hoelmer, Mei Lun Mui, Avin Arjoonsingh, Chen Gilor","doi":"10.1111/jvim.17303","DOIUrl":"10.1111/jvim.17303","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The advantages of insulin degludec 100 U/mL (IDeg100) in the treatment of diabetes mellitus (DM) include consistent release, predictable glucose-lowering effect, and minimal day-to-day variability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis/Objectives</h3>\u0000 \u0000 <p>To describe the use of IDeg100 in dogs with DM, level of diabetic control and adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Thirty-three client-owned dogs with DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective, multi-institutional, uncontrolled study of newly diagnosed or previously insulin-treated, with or without comorbidities and with or without concurrent medications. Clinical signs and continuous glucose monitoring data were monitored and guided insulin dose adjustments. A per-protocol analysis was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The final dose of IDeg100 in dogs was 1.3 U/kg (median, range, 0.4-2.2) achieved in 14 days (median, range, 3-32). Seventy-nine percent (26/33) of the dogs had comorbidities with 42% (11/26) having more than 1 comorbidity. Sixty-four percent (21/33) of dogs were receiving concurrent medications with 62% (13/21) receiving more than 1 non-insulin medication. Seventy-six percent (25/33) were scored as having excellent/very good DM control. From baseline to study exit, dogs showed improvements in both ALIVE DM clinical score (from 3 [0-8, 96.49% CI (2-5)] to 1 [0-7, 96.49% CI (1-2)]; <i>P</i> = .0007) and average 3-day interstitial glucose (from 332.8 ± 68.7 mg/dL, 95% CI [308.8-357.2] to 229.0 ± 56.3 mg/dL [CI 209.0 - 248.9]; <i>P</i> < .0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Insulin degludec 100 U/mL is effective for the treatment of dogs with DM. Eighty-four percent (28/33) of dogs responded to once daily dose of IDeg100 with low frequency of clinical hypoglycemia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The European College of Equine Internal Medicine (ECEIM) Congress and the Journal of Veterinary Internal Medicine (JVIM) are not responsible for the content or dosage recommendations in the abstracts. The abstracts are not peer-reviewed before publication. The opinions expressed in the abstracts are those of the author(s) and may not represent the views or position of the ECEIM. The authors are solely responsible for the content of the abstracts.
Oral Presentation
Friday 15 November 2024, 11.30-11.45
Poster Presentation 1
{"title":"17th European College of Equine Internal Medicine (ECEIM) Congress Copenhagen, Denmark 14-16 November 2024","authors":"","doi":"10.1111/jvim.17292","DOIUrl":"10.1111/jvim.17292","url":null,"abstract":"<p><i>The European College of Equine Internal Medicine (ECEIM) Congress and the Journal of Veterinary Internal Medicine (JVIM) are not responsible for the content or dosage recommendations in the abstracts. The abstracts are not peer-reviewed before publication. The opinions expressed in the abstracts are those of the author(s) and may not represent the views or position of the ECEIM. The authors are solely responsible for the content of the abstracts</i>.</p><p><b>Oral Presentation</b></p><p>Friday 15 November 2024, 11.30-11.45</p><p><b>Poster Presentation 1</b></p>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.
Hypothesis/Objectives
Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.
Animals
In the pharmacokinetic study, 24 beagle dogs were dosed in a 4-period crossover design. In the pharmacodynamic study, 4 mongrel and 2 beagle dogs implanted with telemetry probes were included in a 2-way crossover design.
Methods
Both studies were designed as prospective, randomized crossover trials. Dogs were given single doses of 5 mg/dog of either formulation followed by serial blood sampling for determination of pimobendan and O-desmethyl-pimobendan (ODMP; main metabolite). Because of high variability in the pharmacokinetics, the reference scaled average bioequivalence (RSABE) method was applied. For the pharmacodynamic study, animals were dosed with 0.25 mg/kg of either formulation. Baseline corrected left ventricular maximal pressure (LVdP/dtmax) and heart rate were recorded continuously and compared with a predefined bioequivalence threshold.
Results
Pimobendan was verified as a high variability drug. Based on the RSABE method, both formulations were bioequivalent. Pharmacodynamic results supported bioequivalence.
Conclusions and Clinical Importance
The novel oral solution of pimobendan was found to be bioequivalent, both applying the Food and Drug Administration (FDA) supported RSABE method and based on pharmacodynamic data. Thus, the novel liquid formulation can be used to facilitate accurate dosing of small and toy breed dogs.
{"title":"Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs","authors":"Olaf Kuhlmann, Michael Markert","doi":"10.1111/jvim.17248","DOIUrl":"10.1111/jvim.17248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis/Objectives</h3>\u0000 \u0000 <p>Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>In the pharmacokinetic study, 24 beagle dogs were dosed in a 4-period crossover design. In the pharmacodynamic study, 4 mongrel and 2 beagle dogs implanted with telemetry probes were included in a 2-way crossover design.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Both studies were designed as prospective, randomized crossover trials. Dogs were given single doses of 5 mg/dog of either formulation followed by serial blood sampling for determination of pimobendan and O-desmethyl-pimobendan (ODMP; main metabolite). Because of high variability in the pharmacokinetics, the reference scaled average bioequivalence (RSABE) method was applied. For the pharmacodynamic study, animals were dosed with 0.25 mg/kg of either formulation. Baseline corrected left ventricular maximal pressure (LVdP/dt<sub>max</sub>) and heart rate were recorded continuously and compared with a predefined bioequivalence threshold.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pimobendan was verified as a high variability drug. Based on the RSABE method, both formulations were bioequivalent. Pharmacodynamic results supported bioequivalence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>The novel oral solution of pimobendan was found to be bioequivalent, both applying the Food and Drug Administration (FDA) supported RSABE method and based on pharmacodynamic data. Thus, the novel liquid formulation can be used to facilitate accurate dosing of small and toy breed dogs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah E. Cox, Jennifer Wakeling, Teresa Hall, Tim L. Williams
Background
Hyperthyroid cats that are azotemic and hypothyroid after surgical or medical treatment have poor outcomes, and supplementation with levothyroxine (LT4) improves survival. However, the effect of LT4 supplementation on survival of nonazotemic, hypothyroid radioiodine (RI)-treated hyperthyroid cats is unknown.
Hypothesis
Radioiodine treated hyperthyroid cats with iatrogenic hypothyroidism or azotemia have shorter survival times than euthyroid, nonazotemic cats and supplementation of LT4 improves survival times of hypothyroid cats.
Animals
One hundred seventeen RI treated hyperthyroid cats.
Methods
Prospective cohort study. Radioiodine treated cats were screened for azotemia and iatrogenic hypothyroidism using TSH stimulation test; LT4 supplementation was offered to all hypothyroid cats with decision to treat based on owner preference. The log rank test was used to compare survival times between groups, and the Mann-Whitney U test was used to compare age and renal variables. Data are presented as median [range].
Results
Euthyroid azotemic cats (934 [759-2035] days) and nonsupplemented hypothyroid cats (azotemic and nonazotemic combined, 1232 [238-2363] days) had shorter survival times than euthyroid nonazotemic cats (1616 [663-3369] days, P = .003 and P = .002, respectively). Levothyroxine supplemented hypothyroid nonazotemic cats had longer survival times than nonsupplemented hypothyroid nonazotemic cats (1037 [300-2401] days vs 768 [34-1014] days; P = .027). Levothyroxine supplementation was not associated with prolonged survival times in hypothyroid azotemic cats vs nonsupplemented hypothyroid azotemic cats (771 [718-1558] days vs 152 [82-1852] days, respectively, P = .991).
Conclusions and Clinical Importance
Levothyroxine supplementation in nonazotemic cats with iatrogenic hypothyroidism (diagnosed based on TSH stimulation test results) improved survival times, although randomized controlled trials are needed.
{"title":"Survival of radioiodine treated hyperthyroid cats that are euthyroid and hypothyroid after treatment, and effect of levothyroxine supplementation on survival time of cats with iatrogenic hypothyroidism","authors":"Sarah E. Cox, Jennifer Wakeling, Teresa Hall, Tim L. Williams","doi":"10.1111/jvim.17295","DOIUrl":"10.1111/jvim.17295","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyperthyroid cats that are azotemic and hypothyroid after surgical or medical treatment have poor outcomes, and supplementation with levothyroxine (LT4) improves survival. However, the effect of LT4 supplementation on survival of nonazotemic, hypothyroid radioiodine (RI)-treated hyperthyroid cats is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis</h3>\u0000 \u0000 <p>Radioiodine treated hyperthyroid cats with iatrogenic hypothyroidism or azotemia have shorter survival times than euthyroid, nonazotemic cats and supplementation of LT4 improves survival times of hypothyroid cats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>One hundred seventeen RI treated hyperthyroid cats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective cohort study. Radioiodine treated cats were screened for azotemia and iatrogenic hypothyroidism using TSH stimulation test; LT4 supplementation was offered to all hypothyroid cats with decision to treat based on owner preference. The log rank test was used to compare survival times between groups, and the Mann-Whitney <i>U</i> test was used to compare age and renal variables. Data are presented as median [range].</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Euthyroid azotemic cats (934 [759-2035] days) and nonsupplemented hypothyroid cats (azotemic and nonazotemic combined, 1232 [238-2363] days) had shorter survival times than euthyroid nonazotemic cats (1616 [663-3369] days, <i>P</i> = .003 and <i>P</i> = .002, respectively). Levothyroxine supplemented hypothyroid nonazotemic cats had longer survival times than nonsupplemented hypothyroid nonazotemic cats (1037 [300-2401] days vs 768 [34-1014] days; <i>P</i> = .027). Levothyroxine supplementation was not associated with prolonged survival times in hypothyroid azotemic cats vs nonsupplemented hypothyroid azotemic cats (771 [718-1558] days vs 152 [82-1852] days, respectively, <i>P</i> = .991).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Levothyroxine supplementation in nonazotemic cats with iatrogenic hypothyroidism (diagnosed based on TSH stimulation test results) improved survival times, although randomized controlled trials are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rommaneeya Leela-arporn, Karah Burns DeMarle, Cailin R. Heinze, Cynthia R. L. Webster
Background
Dogs with hepatocutaneous syndrome (HCS) have marked plasma hypoaminoacidemia, but its occurrence in dogs with chronic liver diseases not associated with HCS (non-HCS CLD) is unknown.
Objectives
To determine if plasma hypoaminoacidemia occurs in dogs with non-HCS CLD, compare plasma amino acid (PAA) profiles between dogs with non-HCS CLD and HCS, and define a sensitive and specific PAA pattern for diagnosing HCS.
Animals
Data were collected from client-owned dogs, a prospective cohort of 32 with CLD and 1 with HCS, and a retrospective cohort of 7 with HCS.
Methods
Prospective study. Dogs with chronic serum liver enzyme increases were recruited after hepatic biopsy. Plasma amino acid profiles were measured using high-performance liquid chromatography. Plasma amino acid concentrations were compared between dogs with non-HCS CLD and HCS. Regression analysis was performed to identify a unique PAA pattern for HCS diagnosis.
Results
Twelve dogs each with vacuolar hepatopathy or chronic hepatitis and 8 dogs with congenital disorders (primary hypoplasia of the portal vein or ductal plate malformations) were enrolled. Compared to non-HCS CLD dogs, HCS dogs had significantly lower plasma concentrations of several amino acids. Regression analysis revealed that glutamine, glycine, citrulline, arginine, and proline concentrations less than 30% of the mean reference value had 100% sensitivity, specificity for diagnosing HCS.
Conclusions and Clinical Importance
Generalized plasma hypoaminoacidemia does not accompany non-HCS CLD. Concentrations of 5 specific amino acids less than 30% of the mean reference value can serve as a noninvasive biomarker for diagnosing HCS.
{"title":"Plasma amino acid profiles of dogs with the hepatocutaneous syndrome and dogs with other chronic liver diseases","authors":"Rommaneeya Leela-arporn, Karah Burns DeMarle, Cailin R. Heinze, Cynthia R. L. Webster","doi":"10.1111/jvim.17285","DOIUrl":"10.1111/jvim.17285","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dogs with hepatocutaneous syndrome (HCS) have marked plasma hypoaminoacidemia, but its occurrence in dogs with chronic liver diseases not associated with HCS (non-HCS CLD) is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine if plasma hypoaminoacidemia occurs in dogs with non-HCS CLD, compare plasma amino acid (PAA) profiles between dogs with non-HCS CLD and HCS, and define a sensitive and specific PAA pattern for diagnosing HCS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Data were collected from client-owned dogs, a prospective cohort of 32 with CLD and 1 with HCS, and a retrospective cohort of 7 with HCS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective study. Dogs with chronic serum liver enzyme increases were recruited after hepatic biopsy. Plasma amino acid profiles were measured using high-performance liquid chromatography. Plasma amino acid concentrations were compared between dogs with non-HCS CLD and HCS. Regression analysis was performed to identify a unique PAA pattern for HCS diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twelve dogs each with vacuolar hepatopathy or chronic hepatitis and 8 dogs with congenital disorders (primary hypoplasia of the portal vein or ductal plate malformations) were enrolled. Compared to non-HCS CLD dogs, HCS dogs had significantly lower plasma concentrations of several amino acids. Regression analysis revealed that glutamine, glycine, citrulline, arginine, and proline concentrations less than 30% of the mean reference value had 100% sensitivity, specificity for diagnosing HCS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Generalized plasma hypoaminoacidemia does not accompany non-HCS CLD. Concentrations of 5 specific amino acids less than 30% of the mean reference value can serve as a noninvasive biomarker for diagnosing HCS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mathieu Victor Paulin, Dorsa Mehrabanpour, Suraj Unniappan, Elisabeth C. R. Snead
Background
The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.
Objective
Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.
Animals
Eight healthy neutered young adult research Beagles.
Methods
In our prospective longitudinal study, Beagles were treated with a placebo PO q24h for 15 days (baseline), followed by a 35-day course of prednisolone (2.35-2.75 mg/kg PO q24h) and then abrupt discontinuation of prednisolone. Serial pAVP and sCoP concentrations, urine specific gravity (USG) and calculated plasma osmolality (pOsmcalculated) were determined during placebo and prednisolone administration, and up to 4 weeks after prednisolone discontinuation. Paired plasma samples for pAVP measurement were obtained in EDTA tubes with (pAVPP800) and without (pAVPEDTA) a proprietary combination of protease, esterase, and dipeptidyl peptidase-IV inhibitors (BD Biosciences P800).
Results
Mean pAVPP800 and sCoP concentrations were significantly lower at the end of the prednisolone course (25.8 ± 8.1 pg/mL and 166 pg/mL, range, 131-223) vs baseline (34.1 ± 5.4 pg/mL and 243 pg/mL, range, 157-336; P = .02, P = .02, respectively). Correlations between pAVPP800 and sCoP (r = .77, P = .001) and pAVPP800 and USG (r = .61, P = .02) were positive, despite no correlation between pAVPP800 and pOsmcalculated, sCoP and pOsmcalculated, and sCoP and USG. On paired samples, mean pAVPEDTA was significantly lower (5.0 ± 2.5 pg/mL) than mean pAVPP800 (34.1 ± 5.4 pg/mL; P < .0001).
Conclusions and Clinical Importance
Orally administered prednisolone led to markedly decreased plasma AVP and serum CoP concentrations despite increased calculated plasma osmolality and stable systolic blood pressure.
{"title":"Orally administered prednisolone decreases plasma arginine vasopressin and serum copeptin concentrations in healthy dogs","authors":"Mathieu Victor Paulin, Dorsa Mehrabanpour, Suraj Unniappan, Elisabeth C. R. Snead","doi":"10.1111/jvim.17304","DOIUrl":"10.1111/jvim.17304","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Eight healthy neutered young adult research Beagles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In our prospective longitudinal study, Beagles were treated with a placebo PO q24h for 15 days (baseline), followed by a 35-day course of prednisolone (2.35-2.75 mg/kg PO q24h) and then abrupt discontinuation of prednisolone. Serial pAVP and sCoP concentrations, urine specific gravity (USG) and calculated plasma osmolality (pOsm<sub>calculated</sub>) were determined during placebo and prednisolone administration, and up to 4 weeks after prednisolone discontinuation. Paired plasma samples for pAVP measurement were obtained in EDTA tubes with (pAVP<sub>P800</sub>) and without (pAVP<sub>EDTA</sub>) a proprietary combination of protease, esterase, and dipeptidyl peptidase-IV inhibitors (BD Biosciences P800).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean pAVP<sub>P800</sub> and sCoP concentrations were significantly lower at the end of the prednisolone course (25.8 ± 8.1 pg/mL and 166 pg/mL, range, 131-223) vs baseline (34.1 ± 5.4 pg/mL and 243 pg/mL, range, 157-336; <i>P</i> = .02, <i>P</i> = .02, respectively). Correlations between pAVP<sub>P800</sub> and sCoP (<i>r</i> = .77, <i>P</i> = .001) and pAVP<sub>P800</sub> and USG (<i>r</i> = .61, <i>P</i> = .02) were positive, despite no correlation between pAVP<sub>P800</sub> and pOsm<sub>calculated</sub>, sCoP and pOsm<sub>calculated</sub>, and sCoP and USG. On paired samples, mean pAVP<sub>EDTA</sub> was significantly lower (5.0 ± 2.5 pg/mL) than mean pAVP<sub>P800</sub> (34.1 ± 5.4 pg/mL; <i>P</i> < .0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Orally administered prednisolone led to markedly decreased plasma AVP and serum CoP concentrations despite increased calculated plasma osmolality and stable systolic blood pressure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aran Nagendran, Julie A. Nettifee, Dani Carter, Karen R. Muñana
Background
Post-ictal (PI) clinical signs are a key defining stage of seizure manifestation in dogs. However, this phase remains poorly understood.
Objectives
To further characterize PI signs and their relation to other parts of a seizure, and understand the owner's perception of how PI signs affect the quality of life (QOL) of the dog.
Animals
Eight-seven dogs with a diagnosis of idiopathic epilepsy from a single institution.
Methods
The prospective questionnaire-based study surveying owners of dogs previously and newly diagnosed with idiopathic epilepsy.
Results
Post-ictal signs were identified in 79/87 dogs, 5/5 of dogs with focal seizures and 74/82 of dogs with generalized seizures. Median duration of PI signs was 30 minutes (range, 5-4320 minutes). The most common PI signs reported were disorientation (50/79) and wobbliness or clumsiness (49/79). Within a year, a change in PI signs was seen in 18/79 dogs. The administration of benzodiazepines was significantly associated with an increase in duration of PI signs (P = .04). Post-ictal signs had more impact on dogs' quality of life compared with ictal signs (P < .01). Groupings of co-existing PI signs identified included disorientation, blindness and deafness.
Conclusion
Post-ictal signs are a commonly reported aspect of seizures in dogs with idiopathic epilepsy, both in focal as well as generalized seizures. Co-existence of signs could provide some valuable insight into the relevance of this particular phase of a seizure. Owner-reported signs and documentation emphasize the need for a better understanding of PI signs in dogs with idiopathic epilepsy.
{"title":"Characterization of post-ictal clinical signs in dogs with idiopathic epilepsy: A questionnaire-based study","authors":"Aran Nagendran, Julie A. Nettifee, Dani Carter, Karen R. Muñana","doi":"10.1111/jvim.17302","DOIUrl":"10.1111/jvim.17302","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Post-ictal (PI) clinical signs are a key defining stage of seizure manifestation in dogs. However, this phase remains poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To further characterize PI signs and their relation to other parts of a seizure, and understand the owner's perception of how PI signs affect the quality of life (QOL) of the dog.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Eight-seven dogs with a diagnosis of idiopathic epilepsy from a single institution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The prospective questionnaire-based study surveying owners of dogs previously and newly diagnosed with idiopathic epilepsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Post-ictal signs were identified in 79/87 dogs, 5/5 of dogs with focal seizures and 74/82 of dogs with generalized seizures. Median duration of PI signs was 30 minutes (range, 5-4320 minutes). The most common PI signs reported were disorientation (50/79) and wobbliness or clumsiness (49/79). Within a year, a change in PI signs was seen in 18/79 dogs. The administration of benzodiazepines was significantly associated with an increase in duration of PI signs (<i>P</i> = .04). Post-ictal signs had more impact on dogs' quality of life compared with ictal signs (<i>P</i> < .01). Groupings of co-existing PI signs identified included disorientation, blindness and deafness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Post-ictal signs are a commonly reported aspect of seizures in dogs with idiopathic epilepsy, both in focal as well as generalized seizures. Co-existence of signs could provide some valuable insight into the relevance of this particular phase of a seizure. Owner-reported signs and documentation emphasize the need for a better understanding of PI signs in dogs with idiopathic epilepsy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weihow Hsue, Cortney E. Pelzek, Samantha Siess, Benjamin A. Terhaar, Shana B. Mintz, Romain Pariaut
Background
Left ventricular (LV) volumes can be calculated from various linear, monoplane, and multiplane echocardiographic methods, and the same method can be applied to different imaging views. However, these methods and their variations have not been comprehensively evaluated against real-time 3-dimensional echocardiography (RT3D).
Hypothesis/Objectives
To identify the LV volumetric approaches that produce the least bias and the best agreement with RT3D, and to assess interoperator reproducibility between an experienced and an inexperienced operator.
Animals
Fifty-nine client-owned dogs with myxomatous mitral valve disease (38 Stage B1, 13 Stage B2, 8 Stages C/D) received echocardiograms, with a subset of 28 dogs (14 Stage B1, 10 Stage B2, 4 Stages C/D) imaged by 2 operators.
Methods
Prospective method comparison study. Body weight-indexed end-diastolic and end-systolic LV volumes using linear methods in long- and short-axis views (Teichholz, cube, modified cube), monoplane methods in right parasternal and left apical views (area-length and Simpson's method of discs), biplane Simpson's method of discs, and real-time triplane (RT3P) were compared against RT3D.
Results
The RT3P method exhibited no bias and demonstrated the highest agreement with RT3D. The linear methods showed significant bias and lower agreements for end-diastolic volumes, end-systolic volumes, or both. Volumes derived from different imaging views using the same method showed poor agreement. Both RT3P and RT3D methods demonstrated poor interoperator reproducibility.
Conclusions and Clinical Importance
Incorporating additional dimensions improves bias and agreement in LV volume quantification, but comprehensive clinical experience with RT3P and RT3D is needed to improve consistency across all operators.
{"title":"Effect of additional dimensions and views in the echocardiographic determination of 3-dimensional left ventricular volume in myxomatous mitral valve disease in dogs","authors":"Weihow Hsue, Cortney E. Pelzek, Samantha Siess, Benjamin A. Terhaar, Shana B. Mintz, Romain Pariaut","doi":"10.1111/jvim.17300","DOIUrl":"10.1111/jvim.17300","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Left ventricular (LV) volumes can be calculated from various linear, monoplane, and multiplane echocardiographic methods, and the same method can be applied to different imaging views. However, these methods and their variations have not been comprehensively evaluated against real-time 3-dimensional echocardiography (RT3D).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Hypothesis/Objectives</h3>\u0000 \u0000 <p>To identify the LV volumetric approaches that produce the least bias and the best agreement with RT3D, and to assess interoperator reproducibility between an experienced and an inexperienced operator.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Animals</h3>\u0000 \u0000 <p>Fifty-nine client-owned dogs with myxomatous mitral valve disease (38 Stage B1, 13 Stage B2, 8 Stages C/D) received echocardiograms, with a subset of 28 dogs (14 Stage B1, 10 Stage B2, 4 Stages C/D) imaged by 2 operators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prospective method comparison study. Body weight-indexed end-diastolic and end-systolic LV volumes using linear methods in long- and short-axis views (Teichholz, cube, modified cube), monoplane methods in right parasternal and left apical views (area-length and Simpson's method of discs), biplane Simpson's method of discs, and real-time triplane (RT3P) were compared against RT3D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The RT3P method exhibited no bias and demonstrated the highest agreement with RT3D. The linear methods showed significant bias and lower agreements for end-diastolic volumes, end-systolic volumes, or both. Volumes derived from different imaging views using the same method showed poor agreement. Both RT3P and RT3D methods demonstrated poor interoperator reproducibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions and Clinical Importance</h3>\u0000 \u0000 <p>Incorporating additional dimensions improves bias and agreement in LV volume quantification, but comprehensive clinical experience with RT3P and RT3D is needed to improve consistency across all operators.</p>\u0000 </section>\u0000 </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号